| Characteristic . | DIAD n = 117 . | sEOAD n = 118 . | Significance level (P-value) . |
|---|---|---|---|
| Age at onset, mean (SD) | 43.4 (8.5) | 54.8 (5.0) | <0.001 |
| Age at baseline visit, mean (SD) | 46.8 (9.2) | 59.2 (5.0) | <0.001 |
| Female, n (%) | 62 (52.9) | 67 (56.8) | 0.56 |
| Race/ethnicity | 0.12 | ||
| Non-Hispanic White | 97 (87.4) | 106 (89.8) | |
| Asian | 6(5.4) | 3(2.5) | |
| African American | 1 (0.9) | 3(2.5) | |
| Refuse to state/unknown | 7(6.3) | 5(3.2) | |
| Years of education, mean (SD) | 13.6 (3.5) | 16.3 (2.8) | <0.001 |
| Symptoms duration*, mean (SD) | 3.4 (2.7) | 4.4 (1.8) | 0.001 |
| Hypertension, n (%) | 14(11.9) | 30 (25.4) | <0.001 |
| Cardiovascular disease, n (%) | 1(0.9) | 2 (1.7) | 0.16 |
| Cerebrovascular disease, n (%) | 1(0.9) | 0 | |
| Diabetes mellitus, n (%) | 3(2.6) | 3 (2.5) | 0.08 |
| Co-morbidity (2 or more), n (%) | 2(1.7) | 1 (0.8) | 0.32 |
| APOE-ε4(+), n (%) | 33 (28.2) | 59 (50.0) | 0.001 |
| PSEN1, n (%) | 87 (74.4) | 0 | |
| PSEN2, n (%) | 9 (7.7) | 0 | |
| APP, n (%) | 21 (17.9) | 0 | |
| MMSE, mean (SD) | 22.0 (6.9) | 21.3 (5.7) | 0.38 |
| CDR, n (%) | |||
| 0.5 | 75 (64.1) | 67 (56.8) | 0.25 |
| 1 | 30 (25.6) | 50 (42.4) | 0.01 |
| 2/3 | 12 (10.2) | 1 (0.85) | 0.03 |
| CDR-SB at baseline, mean (SD) | 3.9 (3.9) | 4.0 (1.9) | 0.71 |
| NPI-Q at baseline | 8.3 (7.1) | 6.1 (7.6) | 0.02 |
| GDS | 3.9 (3.2) (n = 115) | 3.4 (2.7) (n = 84) | 0.18 |
| Baseline motor Symptoms, n (%) | 38 (32.5) | 20 (16.9) | 0.01 |
| Last visit motor symptoms, n (%) | 54 (46.2) | 30 (25.4) | <0.001 |
| Clinical Presentation | |||
| Amnestic | 107 (91.5) | 51 (43.2) | <0.001 |
| Non-Amnestic | 10 (8.5) | 67 (56.8) |
| Characteristic . | DIAD n = 117 . | sEOAD n = 118 . | Significance level (P-value) . |
|---|---|---|---|
| Age at onset, mean (SD) | 43.4 (8.5) | 54.8 (5.0) | <0.001 |
| Age at baseline visit, mean (SD) | 46.8 (9.2) | 59.2 (5.0) | <0.001 |
| Female, n (%) | 62 (52.9) | 67 (56.8) | 0.56 |
| Race/ethnicity | 0.12 | ||
| Non-Hispanic White | 97 (87.4) | 106 (89.8) | |
| Asian | 6(5.4) | 3(2.5) | |
| African American | 1 (0.9) | 3(2.5) | |
| Refuse to state/unknown | 7(6.3) | 5(3.2) | |
| Years of education, mean (SD) | 13.6 (3.5) | 16.3 (2.8) | <0.001 |
| Symptoms duration*, mean (SD) | 3.4 (2.7) | 4.4 (1.8) | 0.001 |
| Hypertension, n (%) | 14(11.9) | 30 (25.4) | <0.001 |
| Cardiovascular disease, n (%) | 1(0.9) | 2 (1.7) | 0.16 |
| Cerebrovascular disease, n (%) | 1(0.9) | 0 | |
| Diabetes mellitus, n (%) | 3(2.6) | 3 (2.5) | 0.08 |
| Co-morbidity (2 or more), n (%) | 2(1.7) | 1 (0.8) | 0.32 |
| APOE-ε4(+), n (%) | 33 (28.2) | 59 (50.0) | 0.001 |
| PSEN1, n (%) | 87 (74.4) | 0 | |
| PSEN2, n (%) | 9 (7.7) | 0 | |
| APP, n (%) | 21 (17.9) | 0 | |
| MMSE, mean (SD) | 22.0 (6.9) | 21.3 (5.7) | 0.38 |
| CDR, n (%) | |||
| 0.5 | 75 (64.1) | 67 (56.8) | 0.25 |
| 1 | 30 (25.6) | 50 (42.4) | 0.01 |
| 2/3 | 12 (10.2) | 1 (0.85) | 0.03 |
| CDR-SB at baseline, mean (SD) | 3.9 (3.9) | 4.0 (1.9) | 0.71 |
| NPI-Q at baseline | 8.3 (7.1) | 6.1 (7.6) | 0.02 |
| GDS | 3.9 (3.2) (n = 115) | 3.4 (2.7) (n = 84) | 0.18 |
| Baseline motor Symptoms, n (%) | 38 (32.5) | 20 (16.9) | 0.01 |
| Last visit motor symptoms, n (%) | 54 (46.2) | 30 (25.4) | <0.001 |
| Clinical Presentation | |||
| Amnestic | 107 (91.5) | 51 (43.2) | <0.001 |
| Non-Amnestic | 10 (8.5) | 67 (56.8) |
APOE-ε4(+) refers to presence of at least one ε4 allele of apolipoprotein E. Co-morbidity was defined as having two or more non-communicable disorders (e.g. diabetes mellitus and hypertension) or illnesses co-occurring in the same participant. *Symptom duration was defined as the time (years) from age at first progressive symptom to baseline assessment. Motor signs were considered to be present if evidence of parkinsonism, gait disorder, early falls, tremor and pyramidal signs. Significant differences are highlighted as bold values. APP, amyloid precursor protein; CDR, Clinical Dementia Rating Scale (scores range from 0 to 3, with higher scores indicating worse cognition and daily function); CDR-SB, Clinical Dementia Rating Scale Sum of Boxes (scores range from 0 to 18, with higher scores indicating worse cognition and daily function); GDS, Geriatric Depression Scale; NPI-Q, Neuropsychiatric Inventory Questionnaire; PSEN1, presenilin 1; PSEN2, presenilin 2.
| Characteristic . | DIAD n = 117 . | sEOAD n = 118 . | Significance level (P-value) . |
|---|---|---|---|
| Age at onset, mean (SD) | 43.4 (8.5) | 54.8 (5.0) | <0.001 |
| Age at baseline visit, mean (SD) | 46.8 (9.2) | 59.2 (5.0) | <0.001 |
| Female, n (%) | 62 (52.9) | 67 (56.8) | 0.56 |
| Race/ethnicity | 0.12 | ||
| Non-Hispanic White | 97 (87.4) | 106 (89.8) | |
| Asian | 6(5.4) | 3(2.5) | |
| African American | 1 (0.9) | 3(2.5) | |
| Refuse to state/unknown | 7(6.3) | 5(3.2) | |
| Years of education, mean (SD) | 13.6 (3.5) | 16.3 (2.8) | <0.001 |
| Symptoms duration*, mean (SD) | 3.4 (2.7) | 4.4 (1.8) | 0.001 |
| Hypertension, n (%) | 14(11.9) | 30 (25.4) | <0.001 |
| Cardiovascular disease, n (%) | 1(0.9) | 2 (1.7) | 0.16 |
| Cerebrovascular disease, n (%) | 1(0.9) | 0 | |
| Diabetes mellitus, n (%) | 3(2.6) | 3 (2.5) | 0.08 |
| Co-morbidity (2 or more), n (%) | 2(1.7) | 1 (0.8) | 0.32 |
| APOE-ε4(+), n (%) | 33 (28.2) | 59 (50.0) | 0.001 |
| PSEN1, n (%) | 87 (74.4) | 0 | |
| PSEN2, n (%) | 9 (7.7) | 0 | |
| APP, n (%) | 21 (17.9) | 0 | |
| MMSE, mean (SD) | 22.0 (6.9) | 21.3 (5.7) | 0.38 |
| CDR, n (%) | |||
| 0.5 | 75 (64.1) | 67 (56.8) | 0.25 |
| 1 | 30 (25.6) | 50 (42.4) | 0.01 |
| 2/3 | 12 (10.2) | 1 (0.85) | 0.03 |
| CDR-SB at baseline, mean (SD) | 3.9 (3.9) | 4.0 (1.9) | 0.71 |
| NPI-Q at baseline | 8.3 (7.1) | 6.1 (7.6) | 0.02 |
| GDS | 3.9 (3.2) (n = 115) | 3.4 (2.7) (n = 84) | 0.18 |
| Baseline motor Symptoms, n (%) | 38 (32.5) | 20 (16.9) | 0.01 |
| Last visit motor symptoms, n (%) | 54 (46.2) | 30 (25.4) | <0.001 |
| Clinical Presentation | |||
| Amnestic | 107 (91.5) | 51 (43.2) | <0.001 |
| Non-Amnestic | 10 (8.5) | 67 (56.8) |
| Characteristic . | DIAD n = 117 . | sEOAD n = 118 . | Significance level (P-value) . |
|---|---|---|---|
| Age at onset, mean (SD) | 43.4 (8.5) | 54.8 (5.0) | <0.001 |
| Age at baseline visit, mean (SD) | 46.8 (9.2) | 59.2 (5.0) | <0.001 |
| Female, n (%) | 62 (52.9) | 67 (56.8) | 0.56 |
| Race/ethnicity | 0.12 | ||
| Non-Hispanic White | 97 (87.4) | 106 (89.8) | |
| Asian | 6(5.4) | 3(2.5) | |
| African American | 1 (0.9) | 3(2.5) | |
| Refuse to state/unknown | 7(6.3) | 5(3.2) | |
| Years of education, mean (SD) | 13.6 (3.5) | 16.3 (2.8) | <0.001 |
| Symptoms duration*, mean (SD) | 3.4 (2.7) | 4.4 (1.8) | 0.001 |
| Hypertension, n (%) | 14(11.9) | 30 (25.4) | <0.001 |
| Cardiovascular disease, n (%) | 1(0.9) | 2 (1.7) | 0.16 |
| Cerebrovascular disease, n (%) | 1(0.9) | 0 | |
| Diabetes mellitus, n (%) | 3(2.6) | 3 (2.5) | 0.08 |
| Co-morbidity (2 or more), n (%) | 2(1.7) | 1 (0.8) | 0.32 |
| APOE-ε4(+), n (%) | 33 (28.2) | 59 (50.0) | 0.001 |
| PSEN1, n (%) | 87 (74.4) | 0 | |
| PSEN2, n (%) | 9 (7.7) | 0 | |
| APP, n (%) | 21 (17.9) | 0 | |
| MMSE, mean (SD) | 22.0 (6.9) | 21.3 (5.7) | 0.38 |
| CDR, n (%) | |||
| 0.5 | 75 (64.1) | 67 (56.8) | 0.25 |
| 1 | 30 (25.6) | 50 (42.4) | 0.01 |
| 2/3 | 12 (10.2) | 1 (0.85) | 0.03 |
| CDR-SB at baseline, mean (SD) | 3.9 (3.9) | 4.0 (1.9) | 0.71 |
| NPI-Q at baseline | 8.3 (7.1) | 6.1 (7.6) | 0.02 |
| GDS | 3.9 (3.2) (n = 115) | 3.4 (2.7) (n = 84) | 0.18 |
| Baseline motor Symptoms, n (%) | 38 (32.5) | 20 (16.9) | 0.01 |
| Last visit motor symptoms, n (%) | 54 (46.2) | 30 (25.4) | <0.001 |
| Clinical Presentation | |||
| Amnestic | 107 (91.5) | 51 (43.2) | <0.001 |
| Non-Amnestic | 10 (8.5) | 67 (56.8) |
APOE-ε4(+) refers to presence of at least one ε4 allele of apolipoprotein E. Co-morbidity was defined as having two or more non-communicable disorders (e.g. diabetes mellitus and hypertension) or illnesses co-occurring in the same participant. *Symptom duration was defined as the time (years) from age at first progressive symptom to baseline assessment. Motor signs were considered to be present if evidence of parkinsonism, gait disorder, early falls, tremor and pyramidal signs. Significant differences are highlighted as bold values. APP, amyloid precursor protein; CDR, Clinical Dementia Rating Scale (scores range from 0 to 3, with higher scores indicating worse cognition and daily function); CDR-SB, Clinical Dementia Rating Scale Sum of Boxes (scores range from 0 to 18, with higher scores indicating worse cognition and daily function); GDS, Geriatric Depression Scale; NPI-Q, Neuropsychiatric Inventory Questionnaire; PSEN1, presenilin 1; PSEN2, presenilin 2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
